RETROVIR by GSK is [see microbiology ()] . Approved for maternal-fetal hiv-1 transmission [see dosage, administration ()], combination with other antiretroviral agents for the treatment of hiv-1 infection. First approved in 1995.
Drug data last refreshed 16h ago · AI intelligence enriched 2mo ago
RETROVIR (zidovudine) is an oral nucleoside reverse transcriptase inhibitor (NRTI) approved in 1995 for HIV-1 treatment and prevention of maternal-fetal transmission. It works by inhibiting HIV-1 reverse transcriptase, blocking viral replication. RETROVIR is typically used in combination with other antiretroviral agents as part of highly active antiretroviral therapy (HAART).
As LOE approaches, the RETROVIR team is likely consolidating and focusing on lifecycle management and generic mitigation strategies rather than growth initiatives.
[see Microbiology ()] .
Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)
A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood
A Multicenter Trial To Evaluate Oral Retrovir in the Treatment of Children With Symptomatic HIV Infection
A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone
The Effect of Fish Oil Plus Fenofibrate on Triglyceride Levels in People Taking Highly Active Antiretroviral Therapy (HAART)
Worked on RETROVIR at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on RETROVIR offers limited career growth potential as the product approaches LOE; opportunities are concentrated in defensive commercial roles (managed care, patient assistance, generic mitigation) and regulatory maintenance. This assignment is best suited for mid-to-late-career professionals seeking stability or specialists in lifecycle management rather than high-growth brand-building.